[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367650-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367650-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","clinical-needs-and-pathology-answers-in-neuroendocrine-neoplasms-of-the-lung","Clinical needs and pathology answers in neuroendocrine neoplasms of the lung","","Lung neuroendocrine neoplasms (NENs) include typical carcinoid, atypical carcinoid, large cell neuroendocrine carcinoma, and small cell lung carcinoma, spanning low- to high-grade malignancies with distinct clinical behavior. Through a structured clinician–pathologist dialogue, the article formulates a practical question-and-answer framework covering differential diagnosis, combined subtypes, primary and metastatic assessment, limited diagnostic samples, predictive biomarkers, tumor staging, and standardized terminology. The approach aims to support shared clinical decision-making and improve delineation of lung NENs.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/clinical-needs-and-pathology-answers-in-neuroendocrine-neoplasms-of-the-lung/367650/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/clinical-needs-and-pathology-answers-in-neuroendocrine-neoplasms-of-the-lung/367650.png","ImageObject",300,407,{"name":42,"@type":43},"Terk","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are lung neuroendocrine neoplasms and why do clinicians need a shared approach?","Question",{"text":63,"@type":64},"Lung NENs comprise low- to high-grade neuroendocrine tumors and carcinomas with clinically compelling distinctions. The article emphasizes a practical shared approach between oncologists and pathologists to improve decision-making.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which topics are addressed in the question-and-answer framework?",{"text":68,"@type":64},"The framework covers differential diagnosis, combined subtypes, primary and metastatic tumors, handling small diagnostic material, predictive biomarkers, tumor staging, and standardizing terminology.",{"name":70,"@type":61,"acceptedAnswer":71},"How does the classification distinguish NETs from NECs in lung NENs?",{"text":72,"@type":64},"NETs are considered relatively well-differentiated and include typical and atypical carcinoid categories, while NECs are high-grade carcinomas with small- or large-cell components, using current diagnostic criteria such as the 2021 WHO classification.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367650,1790579588,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146},1099525198933,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","PATHOLOGICA 2025;117:220-242; DOI: 10.32074/1591-951X-1102  \nReceived: March 5, 2025  \nAccepted: March 25, 2025  \nCorrespondence  \nGiuseppe Pelosi  \nE-mail: [giuseppe.pelosi@unimi.it](giuseppe.pelosi@unimi.it)  \nHow to cite this article: Pelosi G, Laffi A, Papotti M, et al. Clinical needs and pathology answers in neuroendocrine neoplasms of the lung. Pathologica 2025;117:220-242; [https://](https://)[ ](https://)[doi.org/10.32074/1591-951X-1](doi.org/10.32074/1591-951X-1)102  \n© Copyright by Società Italiana di Anatomia Patologica e Citopatologia Diagnostica, Divisione Italiana della International Academy of Pathology  \n OPEN ACCESS  \nThis is an open access journal distributed in accordance with the CC-BY-NC-ND (Creative Commons AttributionNonCommercial-NoDerivatives 4.0 International) license: the work can be used by mentioning the author and the license, but only for non-commercial purposes and only in the original version. For further information: [https://creativecommons](https://creativecommons). org/licenses/by-nc-nd/4.0/deed.en  \nReview  \nClinical needs and pathology’s answers in neuroendocrine neoplasms of the lung  \nGiuseppe Pelosi1,2 *, Alice Laffi3 *, Mauro Papotti4 , Sylvie Lantuejoul5 , Jean-Yves Scoazec6 , Maria Gemelli7 , Riccardo Ricotta7 , Sergio Harari8,9 , Eleonora Duregon4 , Riccardo Papa2 , Angelica Sonzogni10 , Fabrizio Bianchi11 , Antonino Bruno12,13 , Barbara Bassani12 , Silvia Uccella14,15 , Carlo Carnaghi16 , Alexia Francesca Bertuzzi3  \n* These authors contributed equally to the work.  \n1 Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; 2 Inter-Hospital Pathology Division, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy; 3 Medical Oncology and Hematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Rozzano, Italy; 4 Department of Oncology, University of Turin, Turin, Italy; 5 Grenoble Alpes University, Department of Biopathology, Centre Léon Bérard & Pathology Research Platform, Cancer Research Center of Lyon, Lyon, France; 6 Department of Pathology, Gustave Roussy Cancer Campus, Villejuif, France, Université Paris Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, Villejuif, France; 7 Medical Oncology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy; 8 Department of Medical Sciences and Community Health, University of Milan, Milan, Italy; 9 Division of Pneumology, MultiMedica Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy; 10 Department of Diagnostic Pathology and Laboratory, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy; 11 Cancer Biomarker Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy; 2 Innate Immunity Laboratory, Unit of Molecular Pathology, Biochemistry and Immunology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy; 13 Immunology and General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy; 14 Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy; 15 Pathology Service, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Rozzano, Milan, Italy; 16 Oncology and Hematology Unit, Humanitas Istituto Clinico Catanese, Misterbianco (CT), Italy  \nSummary  \nLung neuroendocrine neoplasms (NENs) make up a variegated ensemble of malignancies encompassing typical carcinoid (TC) and atypical carcinoid (AC) . These are low to intermediate grade neuroendocrine tumors (NETs), and large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC), which are full-fledged high-grade neuroendocrine carcinomas (NECs) showing similar clinical outcomes. Through a peer interaction between oncologist and patholo","cbCaie7vq1tR3EVB","https://ap.wps.com/l/cbCaie7vq1tR3EVB","pdf",4904595,23,"English","# Summary\n## Introduction\n# Review","[{\"question\":\"What are lung neuroendocrine neoplasms and why do clinicians need a shared approach?\",\"answer\":\"Lung NENs comprise low- to high-grade neuroendocrine tumors and carcinomas with clinically compelling distinctions. The article emphasizes a practical shared approach between oncologists and pathologists to improve decision-making.\"},{\"question\":\"Which topics are addressed in the question-and-answer framework?\",\"answer\":\"The framework covers differential diagnosis, combined subtypes, primary and metastatic tumors, handling small diagnostic material, predictive biomarkers, tumor staging, and standardizing terminology.\"},{\"question\":\"How does the classification distinguish NETs from NECs in lung NENs?\",\"answer\":\"NETs are considered relatively well-differentiated and include typical and atypical carcinoid categories, while NECs are high-grade carcinomas with small- or large-cell components, using current diagnostic criteria such as the 2021 WHO classification.\"}]","Clinical needs and pathology answers in neuroendocrine neoplasms of the lung | PDF",1790171776,58]